Marijuana compounds show promise in treatment of cardiac disease

January 16, 2017 by Alexander Stokes, Phd, University of Hawaii at Manoa
Marijuana compounds show promise in treatment of cardiac disease
Dr. Alexander Stokes in his JABSOM laboratory. Credit: University of Hawaii at Manoa

A Nevada company is hoping to develop new medicines for heart failure using compounds in marijuana and a novel therapy identified by a University of Hawaiʻi at Mānoa researcher.

Dr. Alexander Stokes, assistant research professor in the Department of Cell and Molecular Biology at the UH John A. Burns School of Medicine, obtained a U.S. patent for his in 2015. The patent claims the cannabinoid receptor TRPV1 can be regulated therapeutically by plant-based cannabinoids.

Cannabinoids include psychoactive and non-psychoactive compounds derived from marijuana, both of which have medicinal properties. They exert their effects inside cells after binding to receptor proteins in the cell membranes, such as TRPV1 and the classical cannabinoid receptors, CB1 and CB2.

Pharmaceutical development company GrowBlox Life Sciences LLC, a wholly owned subsidiary of GB Sciences Inc., obtained the license for Stokes' intellectual therapy last December from Makai Biotechnology LLC, a Hawaiʻi-based cardiovascular therapy company founded by Stokes.

"Cardiovascular disease is the leading global cause of death, accounting for more than 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030," said Dr. Stokes. In the U.S, he explained, this equates to one in three deaths, about one every 40 seconds, and costs the country approximately $316.6 billion a year.

Patients urgently need new drugs that can prevent or reverse the stages of cardiac disease and , according to Dr. Stokes. He further explained that TRPV1 is clearly a major cellular receptor involved in the progression to heart failure, and there is great potential for the new, proprietary mixtures within the GB Life Sciences portfolio to regulate the TRPV1 cannabinoid receptor.

GB Sciences said licensing the TRPV1 patent is a major step in its commitment to discovering new drugs that interact with the non-classical cannabinoid receptors, in addition to binding to the better characterized CB1 and CB2 cannabinoid receptors.

"Our vision of novel, patentable cannabis-based formulations in the treatment of major diseases is now married with a proven drug target for modulation of adverse outcomes in cardiovascular disease," said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences.

Cannabinoids in native plant extracts exerted a more significant effect on TRPV1 receptors than purified cannabinoids in published research reports.

"GB Sciences believes its cannabis-plant-based approach may provide additional clinical benefits to patients due to the 'entourage effect.' In addition, the side effect profiles of cannabis-based therapies have generally been well tolerated," said Dr. Small-Howard. The "entourage effect" refers to the theory that some cannabis compounds have greater effects on the human body when combined with other compounds than when given alone.

Said GB Sciences CEO John Poss, "This license is an important step in our company's march to successful drug discovery. We are very proud of Dr. Small-Howard and her team, and we expect results from this effort that will enable the company to do well by doing good for literally millions of cardiac patients around the world."

Explore further: Patent awarded to medical school scientist for new heart failure therapy

Related Stories

Patent awarded to medical school scientist for new heart failure therapy

August 25, 2015
A patent has been issued by the U.S. Patent and Trademark Office to a University of Hawai'i at Mānoa medical researcher who has developed a novel therapy to treat and prevent heart failure.

Scientists reveal non-addictive pathway to pain relief

January 12, 2017
OHSU research suggests an avenue for developing treatments for chronic pain that harness the medicinal properties of cannabis while minimizing the threat of addiction.

Pain relief without the high

January 4, 2017
Researchers at Leiden University led by Mario van der Stelt (Leiden Institute for Chemistry) have set 'gold standards' for developing new painkillers based on the medicinal effects of cannabis. Publication in Nature Communications.

Medical marijuana helpful for cancer-linked symptoms

December 18, 2014
(HealthDay)—Cannabis and cannabinoid pharmaceuticals can be helpful for nausea and vomiting, pain, and weight loss associated with cancer, according to research published online Dec. 10 in CA: A Cancer Journal for Clinicians.

Synthetic cannabinoids versus natural marijuana—a comparison of expectations

April 27, 2016
An article entitled "Comparison of Outcome Expectancies for Synthetic Cannabinoids and Botanical Marijuana," from The American Journal of Drug and Alcohol Abuse, studied the expected outcomes of both synthetic and natural ...

Recommended for you

Breakthrough article on mechanistic features of microRNA targeting and activity

March 23, 2018
Giovanna Brancati and Helge Grosshans from the FMI have described target specialization of miRNAs of the let-7 family. They identified target site features that determine specificity, and revealed that specificity can be ...

Boosting enzyme may help improve blood flow, fitness in elderly

March 22, 2018
As people age, their blood-vessel density and blood flow decrease, which is why it's harder to maintain muscle mass after 40 and endurance in the later decades, even with exercise. This vascular decline is also one of the ...

Scientists pinpoint cause of vascular aging in mice

March 22, 2018
We are as old as our arteries, the adage goes, so could reversing the aging of blood vessels hold the key to restoring youthful vitality?

Sulfur amino acid restriction diet triggers new blood vessel formation in mice

March 22, 2018
Putting mice on a diet containing low amounts of the essential amino acid methionine triggered the formation of new blood vessels in skeletal muscle, according to a new study from Harvard T.H. Chan School of Public Health. ...

Cold can activate body's 'good' fat at a cellular level, study finds

March 21, 2018
Lower temperatures can activate the body's 'good' fat formation at a cellular level, a new study led by academics at The University of Nottingham has found.

Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning

March 21, 2018
A new study by Dana-Farber Cancer Institute scientists suggests it may be possible to prevent tumors from recurring and to eradicate metastatic growths by implanting a gel containing immunotherapy during surgical removal ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.